CORE
🇺🇦Â
 make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants
Authors
A Gaiger
A Hochhaus
+41Â more
Alessandra Iurlo
Caterina De Benedittis
DJ Barnes
DL Gibbons
Domenico Russo
F Castagnetti
Fabrizio Pane
Fausto Castagnetti
Gabriele Gugliotta
Gianantonio Rosti
Giovanni Martinelli
Giuseppe Saglio
H Kantarjian
HM Kantarjian
Jana Linhartova
JH Lipton
JS Chang
K Machova Polakova
Katerina Machova Polakova
Luana Bavaro
M Alikian
M Baccarani
M Marega
Manuela Mancini
Michele Baccarani
Michele Cavo
MS Zabriskie
P Neviani
R Hehlmann
RJ Garg
RT Silver
S Soverini
S Soverini
S Soverini
S Soverini
S Soverini
S Soverini
S Soverini
Simona Soverini
T Hughes
T Skorski
Publication date
Publisher
'Springer Science and Business Media LLC'
Doi
Cite
Abstract
Abstract is not available.
Similar works
Full text
Available Versions
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
info:doi/10.1186%2Fs12885-016-...
Last time updated on 01/04/2019